Amgen Inc. (NASDAQ:AMGN) is O Keefe Stevens Advisory Inc.’s 8th Largest Position

O Keefe Stevens Advisory Inc. grew its position in Amgen Inc. (NASDAQ:AMGN) by 1.0% in the 4th quarter, Holdings Channel.com reports. The fund owned 48,008 shares of the medical research company’s stock after acquiring an additional 457 shares during the quarter. Amgen comprises about 3.9% of O Keefe Stevens Advisory Inc.’s holdings, making the stock its 8th largest position. O Keefe Stevens Advisory Inc.’s holdings in Amgen were worth $12,513,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of AMGN. Sax Wealth Advisors LLC acquired a new position in Amgen in the 4th quarter valued at about $252,000. Somerset Trust Co grew its stake in shares of Amgen by 3.3% in the 4th quarter. Somerset Trust Co now owns 19,183 shares of the medical research company’s stock valued at $5,000,000 after purchasing an additional 621 shares during the last quarter. Merit Financial Group LLC increased its holdings in shares of Amgen by 31.3% in the fourth quarter. Merit Financial Group LLC now owns 18,643 shares of the medical research company’s stock valued at $4,859,000 after purchasing an additional 4,447 shares during the period. Butensky & Cohen Financial Security Inc. raised its stake in shares of Amgen by 2.0% during the fourth quarter. Butensky & Cohen Financial Security Inc. now owns 16,248 shares of the medical research company’s stock worth $4,235,000 after purchasing an additional 312 shares during the last quarter. Finally, Boston Common Asset Management LLC lifted its holdings in shares of Amgen by 3,060.3% during the fourth quarter. Boston Common Asset Management LLC now owns 21,711 shares of the medical research company’s stock worth $5,659,000 after purchasing an additional 21,024 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on AMGN shares. Piper Sandler Companies restated an “overweight” rating and set a $310.00 price objective on shares of Amgen in a research report on Thursday, January 2nd. Redburn Partners cut their price target on shares of Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Barclays lifted their price objective on Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a report on Monday, October 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $405.00 target price on shares of Amgen in a research note on Tuesday, October 22nd. Finally, Royal Bank of Canada decreased their price target on Amgen from $360.00 to $330.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 27th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Amgen currently has a consensus rating of “Hold” and an average target price of $314.91.

Amgen Stock Performance

Amgen stock opened at $272.11 on Friday. The stock has a fifty day moving average price of $275.01 and a 200 day moving average price of $307.49. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The firm has a market capitalization of $146.27 billion, a P/E ratio of 34.84, a PEG ratio of 2.68 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The company had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. Amgen’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter last year, the business earned $4.96 EPS. Equities research analysts anticipate that Amgen Inc. will post 19.57 earnings per share for the current year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be paid a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.50%. Amgen’s dividend payout ratio is currently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.